Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $1.5 million.

  • Arcutis Biotherapeutics' Cash from Financing Activities rose 27461.93% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.2 million, marking a year-over-year decrease of 13581.56%. This contributed to the annual value of $66.2 million for FY2024, which is 3466.24% down from last year.
  • Arcutis Biotherapeutics' Cash from Financing Activities amounted to $1.5 million in Q3 2025, which was up 27461.93% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Cash from Financing Activities peaked at $285.0 million during Q3 2022, and registered a low of -$97.4 million during Q4 2024.
  • For the 5-year period, Arcutis Biotherapeutics' Cash from Financing Activities averaged around $39.7 million, with its median value being $1.2 million (2021).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Cash from Financing Activities soared by 45226349.21% in 2022, and later plummeted by 19810.86% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Cash from Financing Activities (Quarter) stood at $72.9 million in 2021, then tumbled by 98.68% to $962000.0 in 2022, then surged by 10221.1% to $99.3 million in 2023, then crashed by 198.11% to -$97.4 million in 2024, then soared by 101.52% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.4 million for Q2 2025, and $395000.0 during Q1 2025.